Next Generation Imbruvica Performs Well For Acerta In Early Studies
This article was originally published in Scrip
Executive Summary
Acerta Pharma's second generation Bruton's tyrosine kinase (BTK) inhibitor, acalabrutinib (ACP-196), has proved itself to be a more selective, irreversible and improved version in early trials.
You may also be interested in...
Fast-To-Market Play For AstraZeneca's Acalabrutinib With MCL Filing
Never mind MYSTIC, AstraZeneca is pushing the spotlight onto its other oncology assets, and its second-generation BTK inhibitor has just been accepted for filing and given breakthrough status in the US.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.